Growth Metrics

Alnylam Pharmaceuticals (ALNY) Deferred Taxes (2024 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Deferred Taxes for 4 consecutive years, with -$27.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Deferred Taxes rose 74.7% year-over-year to -$27.2 million, compared with a TTM value of -$2.2 million through Dec 2025, up 97.94%, and an annual FY2025 reading of -$2.2 million, up 97.94% over the prior year.
  • Deferred Taxes was -$27.2 million for Q4 2025 at Alnylam Pharmaceuticals, down from $5.6 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $9.7 million in Q2 2025 and bottomed at -$107.4 million in Q4 2024.